AR082980A1 - Inmunogeno sintetico util para generar inmunidad y proteccion contra patogenos a largo plazo - Google Patents
Inmunogeno sintetico util para generar inmunidad y proteccion contra patogenos a largo plazoInfo
- Publication number
- AR082980A1 AR082980A1 ARP110103339A ARP110103339A AR082980A1 AR 082980 A1 AR082980 A1 AR 082980A1 AR P110103339 A ARP110103339 A AR P110103339A AR P110103339 A ARP110103339 A AR P110103339A AR 082980 A1 AR082980 A1 AR 082980A1
- Authority
- AR
- Argentina
- Prior art keywords
- nil
- seq
- immunogen
- tuberculosis
- promiscuous
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 4
- 244000052769 pathogen Species 0.000 title abstract 4
- 230000036039 immunity Effects 0.000 title abstract 2
- 230000007774 longterm Effects 0.000 title 1
- 201000008827 tuberculosis Diseases 0.000 abstract 3
- 230000003834 intracellular effect Effects 0.000 abstract 2
- 230000004726 long-term protective immunity Effects 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- UPAQRWMRKQCLSD-HTIIIDOHSA-N 2,3-dipalmitoyl-S-glycerylcysteine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CSC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC UPAQRWMRKQCLSD-HTIIIDOHSA-N 0.000 abstract 1
- 208000030507 AIDS Diseases 0.000 abstract 1
- 241000283690 Bos taurus Species 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000004554 Leishmaniasis Diseases 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108010038122 S-(2,3-bis(palmitoyloxy)propyl)cysteine Proteins 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 231100000676 disease causative agent Toxicity 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002045 lasting effect Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
- 201000004792 malaria Diseases 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 201000002311 trypanosomiasis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Inmunógeno sintético representado por la fórmula general (1), útil para generar inmunidad protectora a largo plazo contra diversos patógenos intracelulares que son los agentes causales de tuberculosis, leishmaniasis, SIDA, tripanosomiasis, malaria y también alergia, cáncer y un proceso para su preparación. El inmunógeno desarrollado permite evitar la restricción de HLA en humanos y ganado. Además se divulga una vacuna que comprende a dicho inmunógeno para generar una inmunidad protectora duradera contra diversas enfermedades. Dicha vacuna está dirigida contra patógenos intracelulares, en este caso más particularmente el patógeno M. tuberculosis. En la presente los péptidos promiscuos de M. tuberculosis se conjugan con ligandos TLR en especial, Pam2Cys para dirigirlos principalmente a las células dendríticas y por ello generan una inmunidad protectora a largo plazo; en donde en la fórmula (1), X1 = un epítope auxiliar CD4 T promiscuo seleccionado entre las SEQ ID Nº 1 a 98 o nil; X2 = un epítope citotóxico CD8 T promiscuo seleccionado entre las SEQ ID Nº 99 a 103 o nil; cuando X1 = nil; X2 = SEQ ID Nº 99 a 103, y cuando X2 = nil; X1 = SEQ ID Nº 1 a 98; Y = lisina; y S = serina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2172DE2010 | 2010-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082980A1 true AR082980A1 (es) | 2013-01-23 |
Family
ID=44860462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103339A AR082980A1 (es) | 2010-09-14 | 2011-09-14 | Inmunogeno sintetico util para generar inmunidad y proteccion contra patogenos a largo plazo |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9340622B2 (es) |
| EP (1) | EP2616098B1 (es) |
| JP (1) | JP5991976B2 (es) |
| CN (1) | CN103402539B (es) |
| AR (1) | AR082980A1 (es) |
| AU (1) | AU2011303430B2 (es) |
| BR (1) | BR112013005970A2 (es) |
| WO (1) | WO2012035558A2 (es) |
| ZA (1) | ZA201301831B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
| EP2528938A4 (en) | 2010-01-27 | 2013-10-23 | Childrens Medical Center | PROANGIOGENIC FRAGMENTS OF PROMININ 1 AND USES THEREOF |
| US8883717B2 (en) | 2012-03-30 | 2014-11-11 | Artificial Cell Technologies, Inc. | Antigenic compositions and methods |
| CA2953747A1 (en) | 2013-06-28 | 2014-12-31 | Auckland Uniservices Limited | Amino acid and peptide conjugates and conjugation process |
| US10414819B2 (en) | 2013-08-30 | 2019-09-17 | Longhorn Vaccines And Diagnostics, Llc | Monoclonal antibodies that modulate immunity to MTB and enhance immune clearance |
| US10370437B2 (en) | 2013-08-30 | 2019-08-06 | Longhorn Vaccines And Diagnostics, Llc | Antibodies that modulate immunity to drug resistant and latent MTB infections |
| WO2015031787A2 (en) | 2013-08-30 | 2015-03-05 | Longhorn Vaccines And Diagnostics, Llc | Enhancing immunity to tuberculosis |
| CZ305247B6 (cs) * | 2013-09-20 | 2015-07-01 | Ústav molekulární genetiky AV ČR, v.v.i. | Farmaceutický přípravek obsahující difenylenjodonium pro léčení onemocnění vyvolaných parazity čeledi Trypanosomatidae |
| WO2016103192A1 (en) | 2014-12-23 | 2016-06-30 | Margaret Anne Brimble | Amino acid and peptide conjugates and uses thereof |
| WO2016146143A1 (en) * | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
| IL257895B2 (en) | 2015-09-16 | 2024-03-01 | Artificial Cell Tech Inc | Preparations and methods against malaria |
| EA201891639A1 (ru) | 2016-02-26 | 2019-06-28 | Окленд Юнисервисес Лимитед | Аминокислотные и пептидные конъюгаты и способ конъюгации |
| CN106248936B (zh) * | 2016-08-31 | 2018-09-25 | 中国疾病预防控制中心传染病预防控制所 | 结核分枝杆菌抗原蛋白Rv2201及其T细胞表位肽的应用 |
| CN106442983B (zh) * | 2016-08-31 | 2018-07-03 | 中国疾病预防控制中心传染病预防控制所 | 结核分枝杆菌抗原蛋白Rv3793及其T细胞表位肽的应用 |
| MX2019002968A (es) | 2016-09-21 | 2019-10-15 | Amal Therapeutics Sa | Un complejo novedoso que comprende un peptido penetrante de celulas, una carga y un agonista de peptido de tlr para tratamiento de cancer colorrectal. |
| EP3555630B1 (en) | 2016-12-14 | 2023-05-31 | Becton, Dickinson and Company | Methods and compositions for obtaining a tuberculosis assessment in a subject |
| CN109456388B (zh) * | 2018-09-30 | 2021-09-10 | 中国人民解放军陆军军医大学 | 提高重组HpaA对幽门螺旋杆菌感染保护的脂肽及其激发机体免疫应答的方法和制剂 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2239246A (en) | 1989-12-22 | 1991-06-26 | Astra Ab | Protein antigen from Mycobacterium tuberculosis |
| US6818223B2 (en) | 1993-11-23 | 2004-11-16 | The Regents Of The University Of California | Abundant extracellular products and methods for their production and use |
| AU2003249778B2 (en) * | 2002-08-12 | 2010-09-23 | The Council Of The Queensland Institute Of Medical Research | Novel immunogenic lipopeptides comprising T-helper and cytotoxic T lymphocyte (CTL) epitopes |
| KR20080013850A (ko) * | 2005-02-08 | 2008-02-13 | 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 | 면역원성 분자 |
-
2011
- 2011-09-14 WO PCT/IN2011/000630 patent/WO2012035558A2/en active Application Filing
- 2011-09-14 EP EP11774113.2A patent/EP2616098B1/en not_active Not-in-force
- 2011-09-14 BR BR112013005970A patent/BR112013005970A2/pt not_active Application Discontinuation
- 2011-09-14 AU AU2011303430A patent/AU2011303430B2/en not_active Ceased
- 2011-09-14 AR ARP110103339A patent/AR082980A1/es unknown
- 2011-09-14 CN CN201180054827.5A patent/CN103402539B/zh not_active Expired - Fee Related
- 2011-09-14 JP JP2013528835A patent/JP5991976B2/ja not_active Expired - Fee Related
- 2011-09-14 US US13/822,881 patent/US9340622B2/en not_active Expired - Fee Related
-
2013
- 2013-03-11 ZA ZA2013/01831A patent/ZA201301831B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN103402539B (zh) | 2016-02-24 |
| EP2616098A2 (en) | 2013-07-24 |
| AU2011303430A1 (en) | 2013-03-28 |
| CN103402539A (zh) | 2013-11-20 |
| BR112013005970A2 (pt) | 2016-07-05 |
| JP2013538229A (ja) | 2013-10-10 |
| ZA201301831B (en) | 2014-05-28 |
| EP2616098B1 (en) | 2016-04-20 |
| AU2011303430B2 (en) | 2014-09-11 |
| JP5991976B2 (ja) | 2016-09-14 |
| US9340622B2 (en) | 2016-05-17 |
| US20130183377A1 (en) | 2013-07-18 |
| WO2012035558A2 (en) | 2012-03-22 |
| WO2012035558A3 (en) | 2012-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082980A1 (es) | Inmunogeno sintetico util para generar inmunidad y proteccion contra patogenos a largo plazo | |
| MX2015013813A (es) | Vacuna de conjugado de peptido-antigeno de wt1. | |
| CL2018002803A1 (es) | Antagonistas de c5ar solubles | |
| CY1121532T1 (el) | Μεθοδοι παρασκευης συζευγματων | |
| MX2020002660A (es) | Vesiculas extracelulares de prevotella. | |
| ZA202206809B (en) | Hiv vaccines comprising one or more population episensus antigens | |
| UY32874A (es) | Compuestos y composiciones como moduladores de la actividad de tlr | |
| EA200701128A1 (ru) | Рекомбинантные штаммы bcg, обладающие повышенной способностью к высвобождению из эндосомы | |
| AU2015296298A8 (en) | Flagellin-based agents and uses including effective vaccination | |
| MX2012002723A (es) | Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll. | |
| MX2018009990A (es) | Metodos para mejorar la eficacia de una vacuna mediante la administracion de un antagonista il-4r. | |
| MX2015013235A (es) | Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer. | |
| PE20190458A1 (es) | Composiciones de neisseria meningitidis y metodos de las mismas | |
| MX341395B (es) | Compuestos (lipopeptidos basados en cisteina) y composiciones como agonistas de tlr2 usados para el tratamiento de infecciones, inflamaciones, enfermedades respiratorias, etc. | |
| MX2020004338A (es) | Composiciones de peptidos tau fosforilados y sus usos. | |
| CY1120430T1 (el) | Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων | |
| AR115101A1 (es) | Composiciones para el control de patógenos y usos de las mismas | |
| BR112017005524A2 (pt) | segmentos de rna viral como agentes imunomoduladores e componentes de vacina | |
| WO2013082535A3 (en) | Controlled-release peptide compositions and uses thereof | |
| PE20151588A1 (es) | Vacuna contra el virus del dengue | |
| CL2017000845A1 (es) | Inhibidores de gingipaina de lisina | |
| IN2014KN02740A (es) | ||
| PH12019501569A1 (en) | Universal influenza vaccine compositions | |
| AR097029A1 (es) | Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune | |
| CR9759A (es) | Vacuna rotavirus que induce la proteccion cruzada heterotipica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |